Oct. 27 Quick Takes: NIH ends enrollment COVID-19 trial of Lilly’s bamlanivimab; plus Amgen, Kala
NIH trial of Lilly-AbCellera COVID-19 mAb stopped for futility
NIH has ended enrollment in the ACTIV-3 trial of bamlanivimab to treat hospitalized COVID-19 patients due to lack of efficacy when combined with Veklury remdesivir from Gilead Sciences Inc. (NASDAQ:GILD). The mAb from Eli Lilly and Co. (NYSE:LLY) and AbCellera Biologics Inc. is still under evaluation in BLAZE-2, a Phase III post-exposure prophylactic study, as well as two outpatient trials.
Amgen’s lupus therapy picked for FDA’s innovative trial program
Amgen Inc. (NASDAQ:AMGN) said its adaptive trial for systemic lupus erythematosus will be included in FDA’s Complex Innovative Trial Designs pilot program. The Phase II study will test the company’s IL-2 mutein Fc fusion protein efavaleukin alfa (AMG 592)...